Community Oncology Services Global Market Report 2023: Government Investments in Oncology Bolsters $132.5 Billion Industry
April 07, 2023 04:38 ET
|
Research and Markets
Dublin, April 07, 2023 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Opportunities And Strategies To 2032" report has been added to ResearchAndMarkets.com's offering.The...
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
April 05, 2023 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
TOUR de TUSH RAISES MONEY FOR YOUNG ONSET COLORECTAL CANCER RESEARCH
April 05, 2023 07:00 ET
|
Colon Cancer Coalition
Minneapolis, April 05, 2023 (GLOBE NEWSWIRE) -- Tour de Tush, the month-long virtual cycling event, returns again this year. Held from May 1-31, 2023, Tour de Tush is hosted by the Colon Cancer...
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
April 04, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
March 29, 2023 03:01 ET
|
Mainz BioMed NV
Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effectiveTwo mRNA biomarkers found to be particularly valuable in detecting disease signals in advanced adenoma...
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
March 21, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Fight Colorectal Cancer and MiraLAX® Partner to Provide Bathroom on the National Mall for Colorectal Cancer Awareness
March 15, 2023 11:28 ET
|
Fight Colorectal Cancer
Springfield, Mo., March 15, 2023 (GLOBE NEWSWIRE) -- National nonprofit Fight Colorectal Cancer (Fight CRC) and over-the-counter laxative, MiraLAX® are partnering this March, Colorectal Cancer...
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
March 15, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
March 08, 2023 03:01 ET
|
Mainz BioMed NV
Sponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals Patient Education Day in the City of Mainz, Germany, where the Company is headquartered ...
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 06, 2023 16:05 ET
|
Immuneering Corporation
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected...